Biotechnology Californian oncology-focused biotech Avenzo Therapeutics and China-based Duality Biotherapeutics (DualityBio) have entered into an exclusive license agreement, whereby Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate (ADC), globally (excluding Greater China). 8 January 2025